Marizyme, Inc. Appoints Roger Schaller as Executive Vice President of Commercial Operations
January 29, 2021 at 09:12 pm IST
Share
On January 16, 2021, Marizyme, Inc. ('Marizyme') appointed Roger Schaller as Executive Vice President of Commercial Operations. Roger Schaller is the Executive Vice President of Commercial Operations for Marizyme. Mr. Schaller has over 30 years of life science industry experience in commercial operations, business development and, new product development for large and entrepreneurial companies. His experience has been with Medical, Life Sciences, Electronics and Bio Tech products with Global responsibilities and executive leadership. Most recently, Roger Schaller was Vice President of Business Development at Promex Industries.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
